Abstract | PURPOSE: EXPERIMENTAL DESIGN: MMR status was determined by microsatellite instability testing or immunohistochemistry in 303 unselected patients with stage III colon cancer receiving adjuvant FOLFOX chemotherapy in 9 centers. Cox proportional hazards models were used to examine the association between MMR status and 3-year DFS. RESULTS: The 3-year DFS rate was significantly higher in the 34 patients (11.2% of the study population) with defective MMR tumors (90.5%) than in patients with proficient MMR tumors (73.8%; log-rank test; HR = 2.16; 95% CI, 1.09-4.27; P = 0.027). In multivariate analysis, MMR status remained an independent significant prognostic factor for DFS (HR = 4.48; 95% CI, 1.34-14.99; P = 0.015). CONCLUSION:
|
Authors | Aziz Zaanan, Jean-François Fléjou, Jean-François Emile, Guetz Gaëtan Des, Peggy Cuilliere-Dartigues, David Malka, Cédric Lecaille, Pierre Validire, Christophe Louvet, Philippe Rougier, Aimery de Gramont, Franck Bonnetain, Françoise Praz, Julien Taïeb |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 17
Issue 23
Pg. 7470-8
(Dec 01 2011)
ISSN: 1557-3265 [Electronic] United States |
PMID | 21998335
(Publication Type: Journal Article)
|
Copyright | ©2011 AACR. |
Chemical References |
- Biomarkers, Tumor
- Organoplatinum Compounds
- Leucovorin
- Fluorouracil
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biomarkers, Tumor
- Chemotherapy, Adjuvant
- Colonic Neoplasms
(drug therapy, genetics)
- DNA Mismatch Repair
- Disease-Free Survival
- Female
- Fluorouracil
(therapeutic use)
- Humans
- Leucovorin
(therapeutic use)
- Male
- Middle Aged
- Organoplatinum Compounds
(therapeutic use)
- Prognosis
- Proportional Hazards Models
|